Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L22 pseudogene 3 (RPL22P3) is a non-functional processed pseudogene that is homologous to the ribosomal protein L22 gene. Like other pseudogenes, RPL22P3 does not produce a functional protein. It is one of multiple pseudogenes related to the ribosomal protein L22, which is a component of the 60S subunit of cytoplasmic ribosomes and is involved in protein synthesis. RPL22P3 does not have known biological functions, enzyme activity, receptor activity, or roles in signaling pathways or human disease. Its presence has been noted in genetic studies as a processed pseudogene, but it is not considered a therapeutic target or biomarker[1][7]. There are many processed pseudogenes for ribosomal proteins, including RPL22, scattered through the human genome. Pseudogenes like RPL22P3 are generally not transcribed into functional proteins, do not encode receptors, enzymes, or other pharmacological targets, and are not directly implicated in human disease as functional effectors. The functional gene in this family is RPL22, coding for 60S ribosomal protein L22, which is a structural component of ribosomes essential for protein synthesis; its pseudogenes, including RPL22P3, are not active participants in these processes. Historic confusion between cytogenetic loci and actual gene function has occurred, but current annotations clearly define RPL22P3 as a pseudogene. RPL22P3 is not a functional gene or a therapeutic target. It should not be confused with the active ribosomal protein L22, which is protein-coding and relevant in ribosome function. No drugs, mechanisms of action, or roles in disease or therapy are associated with RPL22P3[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L22 pseudogene 3 (RPL22P3).